Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

Analysis of the Nugent score before (T=0) and after (T=1) the use of the vaginal gel. Number of participants and respective percentages of Nugent scores before and after the intervention. A statistically significant decrease in Nugent scores was observed after the intervention (p value =0.0047). by Adriana Bittencourt Campaner (21175462)

“…Number of participants and respective percentages of Nugent scores before and after the intervention. A statistically significant decrease in Nugent scores was observed after the intervention (p value =0.0047).…”

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

Subjects:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

Subjects: